Scorpius Holdings

SCPX · NYSE American

$0.0001+$0.0001 (+0.00%)TodayMarket closed ·
No price history for this range.

About SCPX

Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in San Antonio, Texas and currently employs 89 full-time employees. The company went IPO on 2013-07-24. The firm was previously a contract development and manufacturing organization.

Employees
89
Headquarters
San Antonio, Texas
Listed
Jul 24, 2013
Sector
Health Care
Industry
Biotechnology

SCPX key statistics

Market cap
6.11K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
26.24K
Volume
1
Open price
$0.0001
High today
$0.0001
Low today
$0.0001
52 Week high
$0.10
52 Week low
$0.0001

Scorpius Holdings (SCPX) at a glance

As of Oct 20, 2026, Scorpius Holdings (SCPX) shares are priced at $0.0001, giving the company a market cap of 6.11K and a price-to-earnings ratio of 0.00.

Volume so far is 1 shares, below the average of 26.24K shares a day.

Over the past year Scorpius Holdings has ranged from $0.0001 to $0.10, and now sits 0% of the way up that range.

Scorpius Holdings met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q4 FY23 it reported -$42.00 per share against an estimate of -$44.88.

SCPX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 15.4% on average.

  1. Q3 FY21: reported -$60.00 per share against an estimate of -$62.02
  2. Q4 FY21: reported -$108.00 per share against an estimate of -$65.28
  3. Q1 FY22: reported -$64.00 per share against an estimate of -$100.98
  4. Q2 FY22: reported -$80.00 per share against an estimate of -$58.14
  5. Q4 FY22: reported -$94.88 per share against an estimate of -$87.72
  6. Q2 FY23: reported -$106.00 per share against an estimate of -$91.80
  7. Q3 FY23: reported -$100.00 per share against an estimate of -$71.40
  8. Q4 FY23: reported -$42.00 per share against an estimate of -$44.88

SCPX news

  • Press releaseBusiness Wire

    Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission

  • Avi Kapoor

    Crude Oil Gains 3%; 3M Posts Better-Than-Expected Q1 Results

  • Avi Kapoor

    Dow Jumps Over 400 Points; Verizon Earnings Top Views

  • Avi Kapoor

    Nasdaq Surges Over 300 Points; State Street Earnings Top Views

  • Avi Kapoor

    S&P 500 Gains 1%; Fastenal Posts Downbeat Earnings

  • Avi Kapoor

    Dow Jumps Over 300 Points; US Industrial Production Beats Estimates

  • Avi Kapoor

    Nasdaq Jumps 250 Points; Disney Earnings Beat Estimates

  • Avi Kapoor

    Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Similar companies

Companies in the same industry as Scorpius Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.